Biomet's fourth-quarter results lack sparkle
This article was originally published in Clinica
Executive Summary
Biomet's share price fell by more than 4% in after-hours trading on June 20 after the Warsaw, Indiana orthopaedics company released preliminary fourth-quarter sales figures at the low end of expectations. It also announced management changes in its EBI bone growth stimulation and external fixation business unit.